Steward Raises $8.8M in Series A Funding
23 Sep, 2021
– haemaLogiX from Sydney is a biotech company developing a drug to treat a rare blood disorder.
– The company raised $10M in Series A funding.
– The round was led by Platinum Asset Management via its Platinum International Health Care Fund.
– The investment will be used to support the manufacturing of the next batch of the Kappa antibody plus the conduct of a higher dose, 30mg/kg, monotherapy study and prepare for two further studies.